SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?

The importance of coexisting conditions in chronic lymphocytic leukemia (CLL) outcome has been increasingly recognized over the past years. The role of comorbidities to predict patients' vulnerability toward immunochemotherapy has been well establish, especially since some of the tools commonly used to evaluate patients' fitness were employed to determine treatment eligibility in randomized trials. Nevertheless, is it still unclear how much fitness weights on treatment outcome with targeted agents and which assessment should be preferred. There are key differences in the toxicity profile between novel agents that are getting much more evident in retrospective, real-life experiences, rather than clinical trials. Therefore, an individual patient's comorbid medical conditions may be a deciding factor in therapy selection. Here, we analyze main evidence in literature on the predicting value of comorbidity assessment on outcome and management of CLL patients receiving novel agents.
Competing Interests: Conflict of Interest A.M.F.: Beigene: advisory board, honoraria; Jannsen, Abbvie honoraria; M.M.: Abbvie, Janssen speaker; A.T.: Beigene, Janssen, Abbvie: advisory board, speaker bureau; AstraZeneca: advisory board, M.D., G.Z., C.C. nothing to disclose.
(Copyright © 2021. Published by Elsevier Inc.)